Edwards Lifesciences (EW) closed at $86.61 on Oct 16, 2026, down 1.7% on the day. The stock is down 1.9% over the past month, up 1.9% over three months, up 1.6% year to date and up 18.8% over the past year. It trades 10.1% below its 52-week high of $96.29 and 16.4% above its 52-week low of $74.43. The close sits below its 50-day moving average ($88.42) and above its 200-day moving average ($85.14).
NextPick tracks EW in its Medical Devices basket alongside ABT, ISRG, MDT, SYK and BSX. As of Oct 16, 2026, the basket's money-flow score is 15 (weak inflow), and the basket is up 4.5% over five sessions. Over the past month EW ranks 12th of 13 basket members by price change.
Yes — the Oct 16, 2026 close of $86.61 is 1.7% above the 200-day average of $85.14.
EW closed 10.1% below its 52-week high of $96.29.
NextPick groups EW with ABT, ISRG, MDT, SYK and BSX in its Medical Devices basket.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
